Publications by authors named "Carlos A Carmona-Gonzalez"
Article Synopsis
- * Stigma surrounding MBC, fueled by lack of awareness in the medical field and patient embarrassment, negatively impacts the quality of life, leading to psychological distress and barriers to timely diagnosis and treatment.
- * To improve care for MBC patients, it's essential to increase awareness and understanding within the medical community and develop better screening and treatment guidelines to address the stigma associated with this condition.
Current approaches to the pharmacological management of metastatic breast cancer in older women.
Expert Opin Pharmacother
September 2024
Introduction: A substantial majority of patients diagnosed with metastatic breast cancer consists of individuals 65-year-old or above. Emerging treatment approaches, which utilize genomics-guided therapy and innovative biomarkers, are currently in development. Given the numerous choices in the metastatic context, it is necessary to adopt a personalized approach to decision-making for these patients.
View Article and Find Full Text PDFBridging research gaps in geriatric oncology: unraveling the potential of pragmatic clinical trials.
Curr Opin Support Palliat Care
March 2024
Purpose Of Review: This review examines the role of pragmatic clinical trials (PCTs) in addressing the underrepresentation of older adults with cancer (OAC) in clinical trials. Focusing on real-world evidence (RWE), it aims to provide a comprehensive overview of PCT utilization, emphasizing their potential to enhance treatment decisions and patient outcomes. Existing knowledge gaps in PCT implementation are also discussed.
View Article and Find Full Text PDFIntroduction: Women with metastatic breast cancer (BC) are at risk of developing brain metastases (BrM), which may result in significant morbidity and mortality. Given the emergence of systemic therapies with activity in the brain, more breast oncology clinical trials include patients with BrM, but most require extracranial disease progression for trial participation.
Methods: We evaluated the proportion of patients with BC BrM who have intracranial disease progression in the setting of stable extracranial disease in a retrospective cohort study of 751 patients treated between 2008 and 2018 at the Sunnybrook Odette Cancer.